Previous 10 | Next 10 |
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced th...
Genmab A/S (GMAB) and ADC Therapeutics SA (ADCT) have amended their 2013 collaboration agreement related to continued development and commercialization of antibody-drug conjugate ((ADC)) camidanlumab tesirine (Cami).The revised contract eliminates the defined divestment process and allows ADC...
ADC Therapeutics to continue the development and commercialization of Cami Genmab to receive mid-to-high single-digit tiered royalty Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreem...
Genmab has continued to make great progress since my initial coverage a year ago. The company's portfolio of current and future therapeutics in association with world-class partners bodes well for continued breakthroughs in the fight against cancer. However, one issue of concern m...
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the under...
New Ventures Funds Rebrands as Scientia Ventures PR Newswire NEW YORK, Oct. 2, 2020 NEW YORK , Oct. 2, 2020 /PRNewswire/ -- New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm ...
ADC Therapeutics (ADCT) has priced an upsized IPO of 6M common shares (from 5.5M shares) at $34.00 per share for gross proceeds of $204M.Closing date is September 28.Underwriters can purchase 900K additional shares.The company will not receive any proceeds from the sale of such shares by the ...
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the pricin...
Gainers: NanoVibronix (NAOV) +98%, AIM ImmunoTech (AIM) +29%, Rockwell Medical (RMTI) +22%, Aurora Cannabis (ACB) +16%, Allied Healthcare Products (AHPI) +15%.Losers: Vaccinex (VCNX) -56%, BioSig Technologies (BSGM) -30%, ADC Therape...
Gainers: NanoVibronix (NAOV) +106%.Carvana (CVNA) +33%.AIM ImmunoTech (AIM) +25%.GameStop (GME) +21%.Boxlight (BOXL) +20%.Rockwell Medical (RMTI) +20%.Blink Charging (BLNK) +19%.Natural Alternatives International (NAII) +18%.Issuer Direct (ISDR) +17%.Renren (RENN) +16%.Losers:&...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...